The integration of CeeNU into Septa’s lineup aims to stabilize the supply chain for a medication considered essential for patients battling severe cancer diagnoses. By absorbing this asset, the company strengthens its footprint in the Canadian critical care market while pledging to maintain uninterrupted access for medical professionals and their patients.
In section Releases
Septa Pharmaceuticals Acquires CeeNU from Bristol Myers Squibb Canada
Septa Pharmaceuticals Inc. has finalized the acquisition of CeeNU, an alkylating agent used to treat brain tumors and Hodgkin's lymphoma, from Bristol Myers Squibb Canada. The deal, effective June 29, 2026, signals a major expansion of the Mississauga-based firm's oncology portfolio as it looks to secure long-term drug availability.
Devinder K., President and CEO of Septa Pharmaceuticals, stated that the company is currently coordinating with regulatory bodies and supply chain partners to manage a seamless transition of the drug’s distribution. Beyond this acquisition, Septa is actively pursuing new licensing and commercialization partnerships to broaden its reach in the global pharmaceutical sector, focusing on high-impact therapies.
Comments (0)
No comments yet. Be the first!